Staphylococcus aureus (SA) is a frequent human pathogen carried as a commensal organism in the nares and on the skin of some 30% of the adult population.
1
This organism is a major cause of postoperative surgical site infection 2 and has the potential to cause a broad spectrum of diseases, including sepsis, necrotizing fasciitis, impetigo, osteomyelitis, endocarditis, and toxic shock syndrome. 3 SA has adapted to the pressure of antibiotics, which led to the emergence and global spread of several methicillin-resistant S aureus (MRSA) clones. 4 Resistance to methicillin, in addition to other β-lactam antibiotics, is mediated by the mecA gene located on a mobile genetic element, the staphylococcal cassette chromosome mec (SCCmec), which is widely disseminated in SA. 5, 6 The mecA gene encodes an altered penicillin-binding protein 2a that no longer binds most β-lactam drugs. 5 Currently, 11 SCCmec types (I-XI) are known. [7] [8] [9] [10] SCCmec has been acquired by different lineages of SA, and these MRSA clonal complexes have spread worldwide. [11] [12] [13] SA and MRSA continue as a major source of hospital-associated infections in health care settings worldwide. 14, 15 Infections with SA and MRSA result in significant health care costs. 16 Therefore, active surveillance testing (AST) and isolation and/or decolonization of patients colonized with these potential pathogens are recommended as key measure options to (1) prevent SA surgical site infection and (2) control the spread of MRSA clinical disease.
At the time this study was designed and performed, only two automated molecular diagnostic tests could rapidly and simultaneously detect both SA and MRSA directly from nasal swabs. 20 The assay studied in this report became only the third such test. Our hypothesis was that the development of the cobas MRSA/SA test (Roche Diagnostics, Indianapolis, IN) was robust and would be cleared by the US Food and Drug Administration (FDA) as a laboratory assay for rapid, simultaneous detection of SA and MRSA directly from nasal swabs. Thus, we performed a prospective, multicenter trial to compare this new molecular diagnostic assay with direct and enrichment culture for SA and MRSA.
Materials and Methods

Clinical Trial Using Prospectively Collected Nasal Swabs
Six collection sites in the United States participated in this study, and three sites performed testing with the cobas MRSA/SA test (the other three sites submitted samples to the testing program). Institutional review board approval was obtained prior to the initiation of testing at each site. Inclusion criteria were (1) being willing and able to provide written informed consent and (2) being eligible for the MRSA/SA screening study or by meeting the health care facility's screening policy; the latter could include systematic screening of all patients at admission to hospital or wards (eg, intensive care units, burn units, long-term care facilities, patients admitted for surgery, patients receiving inpatient dialysis treatment, prior MRSA/SA infection or carriage, transfer from another health care facility, prolonged hospital stay or history of prolonged hospitalization, or prolonged contact with an MRSA/SA carrier). Exclusion criteria were (1) antibiotic therapy, either systemic or topical, that was active against MRSA or SA (eg, mupirocin, β-lactam antibiotics, rifampicin, vancomycin, linezolid, daptomycin, clindamycin) 7 days prior to enrollment; (2) contraindication to nasal sampling, as performed according to the collection site policies and procedures; and (3) previous enrollment in the current study.
A total of 2,528 participants were enrolled between September 2013 and July 2014, and 2,504 were evaluable for analyses; 12 (0.5%) were nonevaluable due to three errors in sample collection/storage, nine yielded invalid cobas MRSA/SA test results, and 12 (0.5%) did not meet the study inclusion/exclusion criteria. All adult patients were considered eligible. Two swabs were collected from each participant: one swab for standard-of-care testing and one swab (COPAN MSwab Collection, Transport and Preservation System; Copan Flock Technologies, Brescia, Italy) for the cobas MRSA/SA test as well as for direct and enrichment culture (at the central reference laboratory).
Briefly, on the day of sample collection, the MSwab sample was vortexed and a 300-µL aliquot was aseptically transferred to a sterile, 2-mL polypropylene tube, skirted with an O-ring, and shipped on cold packs to the reference laboratory where culture was performed within 48 hours of collection. The reference laboratory performed all testing for comparison of the cobas MRSA/SA test, which consisted of direct and enriched culture. Direct culture used HardyCHROM MRSA and HardyCHROM S aureus (Hardy Diagnostics, Santa Maria, CA). Presumptive culture isolates were subcultured to 5% sheep blood agar and confirmed as SA using Gram staining, followed by latex agglutination testing using Staphaurex (Remel Microbiology Products; Thermo Fisher Scientific, Lenexa, KS). For enrichment culture, 100 µL MSwab medium was transferred into tryptic soy broth (TSB) with 6.5% NaCl, followed by subculture on blood agar, if turbid growth was observed. Identification and confirmation of presumptive SA colonies recovered from the subcultured 5% sheep blood agar plate were performed using Gram staining, again followed by latex agglutination testing using Staphaurex. Presumptive MRSA isolates were confirmed using the cefoxitin disk screen test for methicillin resistance. Remnant samples from the MSwab were stored at −80°C for future testing.
Testing of Patient Samples on the cobas 4800 System
After receipt of the patient specimen in the laboratory, test orders were logged into the cobas 4800 system either manually, with a work list, or via a laboratory information system connection, and then testing was done. The cobas 4800 system is a walk-away platform performing nucleic acid purification, real-time quantitative polymerase chain reaction (qPCR) setup, amplification, and detection. This system uses the cobas x 480 instrument that includes an automated pipetter to extract, purify, and prepare target nucleic acid for qPCR (eg, automated specimen preparation). Bacterial lysis of the nasal specimen is achieved with proteinase K, detergent, and a chaotropic agent. The purified DNA is bound to magnetic glass particles, washed, and eluted. The cobas x 480 instrument next transfers the working master mix reagent and processes the specimen into the qPCR microwell plate. The plate is then transferred to the cobas z 480 instrument, where amplification and detection of target DNA and controls occur using specific primers © American Society for Clinical Pathology AJCP / Original article and probes. Data analysis and qualitative report generation (positive or negative) are performed by the cobas 4800 software.
Discrepant Analysis
Discrepant analysis was performed on all samples that were discordant between the cobas MRSA/SA test and combined direct and enrichment culture (reference method). In addition, a random subset of concordant samples were tested as controls for the stored remnant samples. This was done using the FDA-cleared Xpert SA Nasal Complete Assay (Cepheid, Sunnyvale, CA) and a nonselective direct and enrichment culture. Briefly, a 100-μL aliquot of remnant MSwab sample was transferred to a chocolate agar plate, and a second 100-μL aliquot was transferred to TSB without NaCl. The Xpert SA Nasal Complete Assay was used to characterize isolates recovered from nonselective direct and enrichment culture as MRSA or SA. In addition, the identification of suspicious, atypical isolates was confirmed using a laboratory-developed qPCR assay for femA and mecA genes according to the established practice of the reference laboratory.
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Analytical Sensitivity, Inclusivity, Specificity, and Reproducibility A limit of detection (LOD) verification study used 35 MRSA isolates and five SA isolates representing common genotypes (including repetitive element types 1, 2, 3, 4, and 6; MRSA SCCmec types I, II, III, IV, V, VI, and VIII; and MRSA pulse-field gel electrophoresis [PFGE] types USA 100 to 1000). Forty replicates of each genotype were tested at three organism densities: LOD was verified if the hit rate in 40 replicates was greater than or equal to 95%. MRSA/SA genetic diversity of this collection is covered by different SCCmec types, MRSA mec right extremity junction types, and spa types found in the species S aureus based on its phylogenetic structure and representative strains of various PFGE types.
In addition to the analytical sensitivity and genotype inclusivity studies, 281 MRSA isolates and 85 SA isolates collected from diverse geographical locations were tested at densities near the detection limit of the cobas MRSA/ SA test. The collection of 281 MRSA isolates was from 16 countries and contained MRSA isolates of different SCCmec types (I, II, III, IV, IVa, V, VI, VII, and new) and 71 spa types, with cefoxitin minimum inhibitory concentration (MIC) values from 6 to greater than 256. The collection of 85 SA isolates from geographically diverse locations within the United States contained SA isolates of 75 different spa types.
To assess the analytical specificity of the cobas MRSA/SA test, 92 bacteria, fungi, and viruses found in nasal swab specimens were tested. These included 43 coagulase-negative Staphylococcus (CoNS) and methicillin-resistant CoNS, as well as 10 borderline methicillin-resistant SA isolates. All bacteria (except for Chlamydophila pneumonia) were spiked to 1 × 10 6 colony-forming units (CFU)/mL or higher, and all viruses were spiked to the highest density allowed by the respective stocks. In addition, 25 commonly used nasal or throat medications, as well as whole blood and mucin, were tested for potential interference effects. All substances were tested at levels above what could be reasonably expected present in a swab collected from a nasal specimen. This was estimated by first determining how much liquid a swab can absorb by weighing the swab before and after immersing in the representative liquid. This volume represents 100% swab capacity, and then the substances are evaluated at levels corresponding to 100%. If there is interference at that concentration, then dilutions are made down to where no interference is observed. For gel-like or solid substances, the volume is converted to weight, and the study is completed in a similar fashion.
Reproducibility of the cobas MRSA/SA test was established in a multisite investigation (three sites, two operators, five days, and two lots of reagent totaling 1,800 tests) using contrived clinical samples evaluated across reagent lot, site/instrument, operator, day, and run. MRSA strains NRS384 (MRSA-384) and ATCC 43300 (MRSA-43300) or SA strain RMSCC 10851 were seeded into simulated clinical MSwab nasal specimens with mucin and human epithelial cells at below LOD, 1 × LOD, and 3 × LOD; a MRSA/SA-negative panel was included as control. Human cells were spiked to 1 × 10 6 cells/mL.
Statistical Analysis of Clinical Samples
SAS/STAT software (SAS Institute, Cary, NC) was used to perform all analyses and create summaries and data listings. The statistical analyses of clinical samples were chosen based on recommendations in guidance from the FDA 22, 23 and in accordance with the guidelines published in Clinical and Laboratory Standards Institute EP12-A2 for evaluating qualitative test performance. 24 The sensitivity, specificity, and positive and negative predictive values of the cobas MRSA/SA test were calculated compared with combined direct and enrichment culture as the reference method. This same analysis was performed for the data after discrepancy analysis and in comparison to direct culture only. The last analysis was done since direct culture is the most common culture method used in the United States.
Results
Performance of the cobas MRSA/SA Test Compared Reference Testing
A total of 2,504 samples collected from eligible patients enrolled at six sites had complete results and were included in the study. Participant demographics are in ❚Table 1❚. There were a total of 160 MRSA-positive and 660 SA-positive specimens. The prevalence across six collection sites was 6.4% for MRSA and 26.4% for SA. Four samples were excluded from the MRSA analysis and three from the SA analysis because of incomplete direct and enrichment culture results. The performance of the cobas MRSA/SA test compared with direct and enrichment culture is shown in ❚Table 2❚. Sensitivity and specificity were not different across the collection sites (data not shown). These same data after discrepancy analysis are in ❚Table 3❚. Using the Xpert SA Nasal Complete Assay and repeat reference culture to resolve discrepant results, the absence of MRSA and SA was confirmed in five (45.4%) of 11 samples and 31 (77.5%) of 40 samples, respectively, that were negative in the cobas MRSA/SA test but positive by combined direct and enrichment culture. Furthermore, testing with the Xpert SA Nasal Complete Assay confirmed the presence of MRSA and SA in 20 (33.9%) of 59 samples and 24 (22.4%) of 107 samples, respectively, that were positives in the cobas MRSA/SA test but negative by combined direct and enriched culture.
For the concordant samples, all 25 concordant MRSA-positive/SA-positive specimens were MRSA positive/SA positive by the Xpert SA Nasal Complete Assay and repeat reference culture; all 25 concordant MRSAnegative/SA-negative specimens were MRSA negative/ SA negative by the Xpert SA Nasal Complete Assay and reference culture. Of the 24 concordant MRSA-negative/ SA-positive specimens, 21 were MRSA negative/SA positive by the Xpert SA Nasal Complete Assay or reference culture, one was MRSA positive/SA positive by the reference culture, and two were MRSA negative/SA negative by the Xpert SA Nasal Complete Assay and reference culture (eg, no significant difference from original testing).
Since most laboratories performing culture for SA and MRSA surveillance only test with direct plate inoculation (no enrichment) using chromogenic agar, 25 we compared the study results with direct chromogenic culture. Strains detected represent at least eight SCCmec types (I, II, III, IV, V, VI, VIII, and new), 10 MRSA mec right extremity junction types, 21 spa types, nine PFGE types, and cefoxitin MIC values of 8 µg/mL or more (range, 8 to ≥32 µg/mL). The LODs for MSSA spa types t002, t008, t018, t088, and t238 were 175 CFU/swab each.
All 85 geographically diverse SA isolates and 277 (98.6%) of 281 MRSA isolates were detected; MRSA stains missed originated from Denmark (one of 37), Australia (one of 6), and France (two of 33); sequencing suggested that the target regions contained sequences not recognized by the primers and probes in the cobas MRSA/SA test. One of the four isolates was a mec A LGA251 (also known as mec C) strain.
The cobas MRSA/SA test was highly reproducible with variances of Ct values from tests performed on positive panel samples ranging from 0.8% to 1.3% for MRSA and 1.2% for SA. The total SD and total coefficient of variation (CV) of Ct values across all MRSA-positive panel members were 0.51% or less and 1.4% or less, respectively. The total SD and total CV of Ct values across all SA-positive panel members were 0.49% or less and 1.3% or less, respectively. The negative percent agreement for the MRSA/SA-negative panel members was 100.0% (95% CI, 98.0%-100.0%).
No interference with detection of intended MRSA or SA targets was detected for other organisms or endogenous substances found in nares. No interference was observed up to 100% of the swab capacity for exogenous substances, except for Relenza (GlaxoSmithKline, Philadelphia, PA), in which no interference was seen up to 6.25% of swab capacity; Rhinaris Nasal Gel (Pendopharm, Montreal, Quebec, Canada), in which no interference occurred up to 15% of swab capacity; Releev (Merix Pharmaceutical, Barrington, IL), with no interference up to 25% of swab capacity (representing the amount of a normal application of the drug); whole blood, with no interference up to 75% of the swab capacity; and mucin, with no interference up to 10% of the swab capacity. No false-positive results were observed with other organisms or substances found in nares.
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Rate of Invalid Results
Among 2,517 specimens tested for MRSA and SA, the initial failure rate was 0.6% (16/2,517), and following one retest, the final failure (invalid) rate was 0.2% (5/2,517).
Discussion
We demonstrated that the cobas MRSA/SA test performed well, with high sensitivity and specificity and a low test failure rate, and that it would be cleared by the FDA as an automated laboratory assay for rapid, simultaneous detection of SA (MSSA) and MRSA directly from nasal swabs. 26 The sensitivity and specificity were demonstrated to be similar to or better than the other FDA-cleared, automated assays that are available for this testing ❚Table 5❚. [26] [27] [28] Diagnostic microbiology laboratories now have at least three options for implementing rapid and sensitive detection of SA and MRSA using fully automated molecular (qPCR) technology, which provides more opportunity to choose an assay that fits Unknown  175  6  6  II  t216  ≥8  USA 100  720  7  2  IV  t008  ≥8  USA 300  350  8  2  II  t037  ≥8  USA 200  700  9  2  IV  t1578  ≥8  USA 300  700  10  2  II  t002  ≥8  USA 100  720  11  2  IV  t008  ≥8  USA 800  750  12  2  IV  t008  ≥8  USA 300  266  13  2  IV  t064  ≥8  USA 500  260  14  2  IV  t148  ≥8  USA 700  700  15  2  IV  t688  ≥8  USA 800  271  16  2  IV  t688  ≥8  USA 300  700  17  2  II  t042  ≥8  USA 100  463  18  2  II  t018  ≥8  USA 200  350  19  2  IV  t008  ≥8  USA 300  410  20  2  IV  t008  ≥8  USA 300  175  21  2  IV  t5576  ≥8  USA 800  202  22  2  II  t004  ≥8  USA 600  350  23  2  IV  t216  ≥8  USA 1000  350  24  2  IV  t064  ≥8  Iberian  175  25  2  II  t266  ≥8  USA 600  700  26  2  IV  t008  ≥8  USA 300  700  27  2  IV  t008  ≥8  USA 300  350  28  2  IV  t002  ≥8  USA 800  350  29  3  V  t242  ≥8  USA 1000  350  30  24  New  t476  ≥8  Unknown  350  31  1  I  t149  ≥8  Unknown  175 the laboratory's workflow needs and potentially lowers cost. The availability of commercial assays that simultaneously detect all SA, while specifically separating MSSA and MRSA, is important for improving health care outcomes in two distinctly specific quality improvement areas. The one that is likely most widely recognized is their use in AST of hospital admissions for MRSA. While this practice is not universally accepted, a recent review found that in the reports of such testing on more than 5 million patients, AST followed by isolation with or without decolonization led to the lowest clinical disease rate-approximately a 10-fold lower rate of clinical MRSA infection that any other approach to MRSA control. 18 In this setting, both speed of result reporting and the sensitivity of the assay are critical for a successful program-both strengths of qPCR assays. The other key area for use of the simultaneous detection of SA and MRSA is in the prevention of postoperative surgical site infection. 2, 14, 20, 29 Preoperative testing coupled with decolonization of those found harboring any SA (eg, MSSA or MRSA) is demonstrated to reduce the risk of significant postoperative infection from these pathogens by four-to fivefold. 14, 29 For this practice, sensitivity is most important since the better the level of detection, the more appropriately patients can be decolonized, and combining the detection of SA and MRSA in a single test facilitates the deployment of these tests in the clinical laboratory. Molecular testing has better demonstrated sensitivity than does culture for SA surveillance. 30 The molecular basis for the development of methicillin resistance in SA is well understood. [5] [6] [7] [8] [9] [10] [11] [12] [13] Thus, the design of primers and probes for a robust real-time PCR assay is very possible, even if challenging. Once established, the analytical performance needs to be validated prior to the initiation of clinical trials. We demonstrated that the cobas MRSA/SA test had robust and excellent analytical sensitivity, inclusivity, and reproducibility prior to the beginning of clinical trials. We also demonstrated that there was minimal interference from other substances possibly found in the anterior nares of patients. Therefore, it was not surprising that the clinical performance of this test was as robust as anticipated. From the laboratory use perspective, we also demonstrated that the initial failure rate of the test was very low, 0.6% (16 of 2,517 tests), which facilitates deployment in the diagnostic microbiology laboratory.
© American Society for Clinical Pathology
For our literature review, we used PubMed.gov (MEDLINE) with the search terms SA/MRSA, simultaneous, PCR, and the names of FDA-cleared tests that simultaneously detect SA and MRSA to search the medical literature from 2005 through August 2016. We also searched Google using these terms as well as www.accessdata.fda.gov to determine what commercial tests were available for these assays.
The cobas MRSA/SA test is one of four FDA-cleared assays for simultaneous detection of SA and MRSA, 31 one of which, the MRSA/SA ELITe MGB assay, 32 is not automated and thus is not included in this discussion. Little is published on the specific performance of any of these assays in detecting MSSA and MRSA other than the 510(k) substantial equivalence determination decision memoranda published by the FDA, which supplied the information included in the recent review of these assays. 20 The only other reports are single-site studies of the Xpert SA Nasal Complete Assay compared with direct and enriched culture, 33 as well as one comparing the cobas MRSA/SA test with direct chromogenic culture. 34 The Xpert assay had a sensitivity of 100% (95% CI, 59.8%-100%) in identifying MRSA nasal colonization with a specificity of 99.8% (95% CI, 99%-100%). For specifically identifying MSSA, the sensitivity in this population was 92.9% (95% CI, 87.3%-96.2%) with a specificity of 98.5% (96.9%-99.4%). 33 In the cobas evaluation, only MRSA was directly analyzed, and the authors found a 
Peterson et al / cobas MRsa/sa TesT PeRfoRMance correlation between the molecular detection of MRSA with culture of 91.3%. 34 Our results on a larger sample in a multicenter trial compare well with these data (Table 4) , where overall sensitivity for SA approached 100% and the sensitivity for MSSA and MRSA specifically was each 97%. The College of American Pathologists proficiency testing program provides some additional data on the sensitivity of detecting MSSA by assays designed to detect all SA as well as specifically MSSA. 25 These challenge samples have known analytes to assess test performance, and in 2016, the summarized performance found the sensitivity of the qPCR assays to be 100% for both MRSA and MSSA, while direct chromogenic culture had a sensitivity of 90% (95% CI, 66.9%-98.2%). 25 Against the challenge tests, qPCR specificity for detecting MRSA was 86.2% (95% CI, 82.4%-89.3%) when tested against a sample containing MSSA. No data could be determined for qPCR specificity against MSSA based on the reported challenge test results. Again, these data support both the earlier study discussed as well as our excellent performance findings for the cobas MRSA/SA test (Table 4) .
Our research had limitations in that there is no "perfect gold standard" for comparison of any new test developed that detects SA and MRSA. However, we are reporting all the comparator methods that were used (eg, direct and enriched culture, direct culture, and an additional qPCR for discrepancy analysis). A useful arbiter of results appears to be other qPCR assays since proficiency testing using defined samples with known targets has shown that the qPCR assays have 100% sensitivity and outperform culture-based tests by 10%. 25 We believe the careful analysis of these clinical trial data is valid based on all the comparisons performed and that we have demonstrated the reliability of this new automated test.
Future research will be useful in comparing the performance and laboratory ease of use for the currently available as well as future assays to detect all SA and specifically identify MSSA and MRSA. This should be a responsibility of both the commercial product developers and the US government to improve the outcome of patients by reducing health care-associated infections and antibiotic-resistant infectious diseases. Also, continued evaluation of the clinical benefit and cost reduction (by preventing clinical MRSA disease and surgical site infection) is useful for disseminating the deployment of these tests and incentivizing of payers for laboratory reimbursement of this highly beneficial testing. The cobas MRSA/ SA test, with mixed-batch testing capability, allows the laboratory to realize gains in efficiency by testing other assays (Clostridium difficile and herpes simplex virus 1/2) simultaneously on the same run, reducing turnaround time. Similarly, the US system menu also includes human papillomavirus, Chlamydia trachomatis/Neisseria gonorrhoeae, and BRAF, EGFR, and KRAS mutation assays that facilitates use of a high-volume instrument.
In conclusion, we have demonstrated that the cobas MRSA/SA test is a reliable and robust automated assay for detection of SA (MSSA and MRSA) and that it reliably distinguishes between these related pathogens. It has entered the commercial testing market with two other SA/MRSA tests as a useful clinical diagnostic tool for the clinical laboratory to use in reducing infectious disease and improving the quality of care for patients.
